Do analysts prefer FEMY or KEQU?

Femasys presently has a consensus price target of $50.00, indicating a potential upside of 1,533.99%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, LNSR or FEMY?

Femasys has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.73 -$34.28M -$0.33 N/A Femasys $2.29M 11.20 -$18.63M -$3.53 N/A

Is LNSR or FEMY more profitable?

LENSAR has a net margin of 57.57% compared to Femasys' net margin of -534.36%. Femasys' return on equity of -225.97% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% Femasys -534.36% -225.97% -74.68%

Is FEMY or MBOT more profitable?

Microbot Medical has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Microbot Medical's return on equity of -21.87% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% Microbot Medical N/A -21.87% -20.76%

Which has stronger valuation and earnings, LUNG or FEMY?

Femasys has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 1.07 -$54M -$1.16 N/A Femasys $2.29M 11.20 -$18.63M -$3.53 N/A

Is LUNG or FEMY more profitable?

Pulmonx has a net margin of -55.03% compared to Femasys' net margin of -534.36%. Pulmonx's return on equity of -96.66% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -96.66% -38.32% Femasys -534.36% -225.97% -74.68%

Which has stronger earnings & valuation, RNXT or FEMY?

RenovoRx has higher earnings, but lower revenue than Femasys. RenovoRx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.12M 95.50 -$11.17M -$0.31 N/A Femasys $2.29M 11.20 -$18.63M -$3.53 N/A

Is RNXT or FEMY more profitable?

Femasys has a net margin of -534.36% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -621.71% -135.11% -101.91% Femasys -534.36% -225.97% -74.68%

Femasys (FEMY) Competitors

$3.06 -0.04 (-1.29%)

As of 09/3/2026 04:00 PM Eastern

Compare

FEMY vs. KEQU, LNSR, MBOT, LUNG, and RNXT

Should you buy Femasys stock or one of its competitors? Femasys's main competitors and comparable companies include Kewaunee Scientific (KEQU), LENSAR (LNSR), Microbot Medical (MBOT), Pulmonx (LUNG), and RenovoRx (RNXT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Femasys compare to Kewaunee Scientific?

Femasys (NASDAQ:FEMY) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

65.3% of Femasys shares are held by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are held by institutional investors. 7.8% of Femasys shares are held by insiders. Comparatively, 14.1% of Kewaunee Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kewaunee Scientific has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	11.20	-$18.63M	-$3.53	N/A
Kewaunee Scientific	$282M	0.37	$9.62M	$3.22	11.43

In the previous week, Kewaunee Scientific had 1 more articles in the media than Femasys. MarketBeat recorded 1 mentions for Kewaunee Scientific and 0 mentions for Femasys. Kewaunee Scientific's average media sentiment score of 1.05 beat Femasys' score of 0.00 indicating that Kewaunee Scientific is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Neutral
Kewaunee Scientific	Positive

Femasys has a beta of -2.07, indicating that its share price is 307% less volatile than the broader market. Comparatively, Kewaunee Scientific has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Femasys presently has a consensus price target of $50.00, indicating a potential upside of 1,533.99%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kewaunee Scientific has a net margin of 3.41% compared to Femasys' net margin of -534.36%. Kewaunee Scientific's return on equity of 14.10% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Kewaunee Scientific	3.41%	14.10%	5.55%

Summary

Kewaunee Scientific beats Femasys on 11 of the 16 factors compared between the two stocks.

How does Femasys compare to LENSAR?

LENSAR (NASDAQ:LNSR) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

LENSAR currently has a consensus price target of $11.50, indicating a potential upside of 39.39%. Femasys has a consensus price target of $50.00, indicating a potential upside of 1,533.99%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

LENSAR has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Femasys has a beta of -2.07, meaning that its share price is 307% less volatile than the broader market.

In the previous week, LENSAR's average media sentiment score of 0.00 equaled Femasys'average media sentiment score.

Company	Overall Sentiment
LENSAR	Neutral
Femasys	Neutral

LENSAR has a net margin of 57.57% compared to Femasys' net margin of -534.36%. Femasys' return on equity of -225.97% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Femasys	-534.36%	-225.97%	-74.68%

Femasys has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.73	-$34.28M	-$0.33	N/A
Femasys	$2.29M	11.20	-$18.63M	-$3.53	N/A

Summary

Femasys beats LENSAR on 8 of the 14 factors compared between the two stocks.

How does Femasys compare to Microbot Medical?

Femasys (NASDAQ:FEMY) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Microbot Medical has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Microbot Medical's return on equity of -21.87% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Microbot Medical	N/A	-21.87%	-20.76%

Femasys has a beta of -2.07, indicating that its share price is 307% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

65.3% of Femasys shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 7.8% of Femasys shares are held by company insiders. Comparatively, 4.7% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Microbot Medical had 1 more articles in the media than Femasys. MarketBeat recorded 1 mentions for Microbot Medical and 0 mentions for Femasys. Microbot Medical's average media sentiment score of 1.02 beat Femasys' score of 0.00 indicating that Microbot Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Neutral
Microbot Medical	Positive

Femasys currently has a consensus target price of $50.00, indicating a potential upside of 1,533.99%. Microbot Medical has a consensus target price of $6.38, indicating a potential upside of 342.71%. Given Femasys' stronger consensus rating and higher probable upside, equities research analysts plainly believe Femasys is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Microbot Medical has lower revenue, but higher earnings than Femasys. Microbot Medical is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	11.20	-$18.63M	-$3.53	N/A
Microbot Medical	N/A	N/A	-$13.14M	-$0.24	N/A

Summary

Microbot Medical beats Femasys on 8 of the 14 factors compared between the two stocks.

How does Femasys compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 7.8% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pulmonx presently has a consensus target price of $7.67, suggesting a potential upside of 239.23%. Femasys has a consensus target price of $50.00, suggesting a potential upside of 1,533.99%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Pulmonx had 12 more articles in the media than Femasys. MarketBeat recorded 12 mentions for Pulmonx and 0 mentions for Femasys. Pulmonx's average media sentiment score of 0.91 beat Femasys' score of 0.00 indicating that Pulmonx is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmonx	Positive
Femasys	Neutral

Pulmonx has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Femasys has a beta of -2.07, meaning that its stock price is 307% less volatile than the broader market.

Pulmonx has a net margin of -55.03% compared to Femasys' net margin of -534.36%. Pulmonx's return on equity of -96.66% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
Femasys	-534.36%	-225.97%	-74.68%

Femasys has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	1.07	-$54M	-$1.16	N/A
Femasys	$2.29M	11.20	-$18.63M	-$3.53	N/A

Summary

Pulmonx beats Femasys on 9 of the 14 factors compared between the two stocks.

How does Femasys compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Femasys has a net margin of -534.36% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-621.71%	-135.11%	-101.91%
Femasys	-534.36%	-225.97%	-74.68%

RenovoRx has higher earnings, but lower revenue than Femasys. RenovoRx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	95.50	-$11.17M	-$0.31	N/A
Femasys	$2.29M	11.20	-$18.63M	-$3.53	N/A

In the previous week, RenovoRx had 11 more articles in the media than Femasys. MarketBeat recorded 11 mentions for RenovoRx and 0 mentions for Femasys. RenovoRx's average media sentiment score of 0.90 beat Femasys' score of 0.00 indicating that RenovoRx is being referred to more favorably in the media.

Company	Overall Sentiment
RenovoRx	Positive
Femasys	Neutral

RenovoRx has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Femasys has a beta of -2.07, suggesting that its share price is 307% less volatile than the broader market.

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

RenovoRx currently has a consensus target price of $8.50, indicating a potential upside of 258.65%. Femasys has a consensus target price of $50.00, indicating a potential upside of 1,533.99%. Given Femasys' higher probable upside, analysts clearly believe Femasys is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

RenovoRx beats Femasys on 10 of the 17 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEMY vs. The Competition

Export

Metric	Femasys	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.96M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-0.87	25.92	273.29	25.38
Price / Sales	11.20	73.28	613.45	92.55
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	6.38	6.04	12.89	6.14
Net Income	-$18.63M	$150.03M	$3.47B	$349.01M
7 Day Performance	-4.38%	-1.32%	0.60%	-0.27%
1 Month Performance	0.33%	1.27%	5.73%	0.68%
1 Year Performance	-58.65%	9.88%	25.35%	14.84%

Femasys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEMY Femasys	2.9126 of 5 stars	$3.06 -1.3%	$50.00 +1,534.0%	-58.6%	$25.96M	$2.29M	N/A	30
KEQU Kewaunee Scientific	1.2622 of 5 stars	$37.67 flat	N/A	-32.7%	$108.11M	$282M	11.70	1,231	Positive News Upcoming Earnings
LNSR LENSAR	2.2336 of 5 stars	$8.46 +0.8%	$11.50 +35.9%	-31.5%	$103.97M	$58.44M	N/A	110	Positive News
MBOT Microbot Medical	2.7202 of 5 stars	$1.47 -1.3%	$6.38 +333.7%	-59.3%	$98.74M	N/A	N/A	20	Gap Up
LUNG Pulmonx	2.9154 of 5 stars	$2.24 -5.9%	$7.67 +242.3%	+36.1%	$96.21M	$90.50M	N/A	250	Trending News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Femasys (FEMY) Competitors

FEMY vs. KEQU, LNSR, MBOT, LUNG, and RNXT

How does Femasys compare to Kewaunee Scientific?

Summary

How does Femasys compare to LENSAR?

Summary

How does Femasys compare to Microbot Medical?

Summary

How does Femasys compare to Pulmonx?

Summary

How does Femasys compare to RenovoRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Femasys (FEMY) Competitors

FEMY vs. KEQU, LNSR, MBOT, LUNG, and RNXT

How does Femasys compare to Kewaunee Scientific?

Do institutionals & insiders believe in FEMY or KEQU?

Which has stronger earnings & valuation, FEMY or KEQU?

Does the media favor FEMY or KEQU?

Which has more volatility & risk, FEMY or KEQU?

Do analysts prefer FEMY or KEQU?

Is FEMY or KEQU more profitable?

Summary

How does Femasys compare to LENSAR?

Do analysts rate LNSR or FEMY?

Do institutionals & insiders hold more shares of LNSR or FEMY?

Which has more volatility & risk, LNSR or FEMY?

Does the media prefer LNSR or FEMY?

Is LNSR or FEMY more profitable?

Which has better earnings and valuation, LNSR or FEMY?

Summary

How does Femasys compare to Microbot Medical?

Is FEMY or MBOT more profitable?

Which has more risk and volatility, FEMY or MBOT?

Do insiders & institutionals believe in FEMY or MBOT?

Does the media favor FEMY or MBOT?

Do analysts rate FEMY or MBOT?

Which has stronger earnings & valuation, FEMY or MBOT?

Summary

How does Femasys compare to Pulmonx?

Do institutionals & insiders have more ownership in LUNG or FEMY?

Do analysts rate LUNG or FEMY?

Does the media prefer LUNG or FEMY?

Which has more risk & volatility, LUNG or FEMY?

Is LUNG or FEMY more profitable?

Which has stronger valuation and earnings, LUNG or FEMY?

Summary

How does Femasys compare to RenovoRx?

Is RNXT or FEMY more profitable?

Which has stronger earnings & valuation, RNXT or FEMY?

Does the media refer more to RNXT or FEMY?

Which has more volatility and risk, RNXT or FEMY?

Do insiders and institutionals believe in RNXT or FEMY?

Do analysts recommend RNXT or FEMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools